Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung, commonly referred to as Nattermann, is a distinguished player in the pharmaceutical and biotechnology industry, headquartered in Germany. Founded in the early 20th century, the company has established a strong presence in Europe and beyond, focusing on the development and production of high-quality active pharmaceutical ingredients (APIs) and intermediates.
Nattermann is renowned for its commitment to innovation and quality, offering a diverse range of products that cater to various therapeutic areas. The company has achieved significant milestones, including strategic partnerships and expansions that have solidified its market position. With a reputation for excellence, A. Nattermann & Cie. continues to contribute to advancements in healthcare, making it a trusted name in the pharmaceutical landscape.
+58 vs industry average
A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung yet.
A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung currently does not report any specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Sanofi, which influences its climate commitments and initiatives.
While A. Nattermann & Cie. does not have its own reduction targets or climate pledges, it inherits sustainability initiatives from its parent company, Sanofi. This includes participation in various climate-related frameworks such as the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded down from Sanofi.
As part of its corporate family, A. Nattermann & Cie. aligns with Sanofi's broader climate strategy, which aims to reduce emissions across all scopes, although specific targets for A. Nattermann & Cie. have not been detailed. The company is expected to contribute to the overarching goals set by Sanofi, focusing on sustainable practices and emissions reduction in the pharmaceutical industry.
In summary, while A. Nattermann & Cie. does not have specific emissions data or reduction targets, it is positioned within a framework of climate commitments inherited from Sanofi, reflecting a commitment to sustainability in its operations.
No climate goals have been disclosed for A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for A. Nattermann & Cie. Gesellschaft Mit Beschränkter Haftung yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more